The divergence in FASN expression between the different types of metastatic tumours could be one of the clinical criteria in deciding whether to treat breast-cancer-metastasised patients using FASN inhibitors based on the anatomical location of the metastasis. The gene discussed is FASN; the disease is breast cancer.